Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma
Authors
Keywords
-
Journal
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-03-04
DOI
10.1002/hed.25726
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells
- (2016) Elizabeth L. McMichael et al. CLINICAL CANCER RESEARCH
- Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients
- (2016) S. Trivedi et al. CLINICAL CANCER RESEARCH
- CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer
- (2016) Raghvendra M. Srivastava et al. CLINICAL CANCER RESEARCH
- A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer
- (2016) E. M. Bertino et al. MOLECULAR CANCER THERAPEUTICS
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells
- (2016) Fernando Concha-Benavente et al. ORAL ONCOLOGY
- Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer
- (2016) John Pradeep Veluchamy et al. PLoS One
- CTLA-4+Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
- (2015) Hyun-Bae Jie et al. CANCER RESEARCH
- Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN That Induce PD-L1 Expression in Head and Neck Cancer
- (2015) F. Concha-Benavente et al. CANCER RESEARCH
- Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes
- (2015) Sachet A Shukla et al. NATURE BIOTECHNOLOGY
- STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients
- (2015) R. M. Srivastava et al. Cancer Immunology Research
- Immune biomarkers of anti-EGFR monoclonal antibody therapy
- (2014) S. Trivedi et al. ANNALS OF ONCOLOGY
- An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
- (2014) Vassiliki Saloura et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Targeting CD137 enhances the efficacy of cetuximab
- (2014) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients
- (2013) R. M. Srivastava et al. CLINICAL CANCER RESEARCH
- Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma
- (2013) Sean M. McBride et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Mutation at Positively Selected Positions in the Binding Site for HLA-C Shows That KIR2DL1 Is a More Refined but Less Adaptable NK Cell Receptor Than KIR2DL3
- (2012) H. G. Hilton et al. JOURNAL OF IMMUNOLOGY
- Cetuximab therapy in head and neck cancer: Immune modulation with interleukin-12 and other natural killer cell–activating cytokines
- (2012) Eric Luedke et al. SURGERY
- Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity
- (2011) Steve C. Lee et al. IMMUNOLOGIC RESEARCH
- HLA-C as a mediator of natural killer and T-cell activation: spectator or key player?
- (2011) Marie-Eve Blais et al. IMMUNOLOGY
- The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
- (2011) N. Stransky et al. SCIENCE
- Inhibitory KIR and specific HLA-C gene combinations confer susceptibility to or protection against chronic hepatitis B
- (2010) Xuejun Gao et al. CLINICAL IMMUNOLOGY
- Activating and inhibitory receptors of natural killer cells
- (2010) Hollie J Pegram et al. IMMUNOLOGY AND CELL BIOLOGY
- Revisiting human natural killer cell subset function revealed cytolytic CD56dimCD16+ NK cells as rapid producers of abundant IFN- on activation
- (2010) A. De Maria et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells
- (2009) Andrés López-Albaitero et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients
- (2009) Jean-Pierre Pignon et al. RADIOTHERAPY AND ONCOLOGY
- FcγRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck
- (2008) Rodney J. Taylor et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More